What is Intellia Therapeutics's gain (loss) on investments?

Intellia Therapeutics (NTLA) reported gain (loss) on investments of -$904K in Q1 2026.

How has Intellia Therapeutics's gain (loss) on investments changed year-over-year?

Intellia Therapeutics's gain (loss) on investments increased by 57.5% year-over-year, from -$2.13M to -$904K.

Ionis PharmaceuticalsIONS

——

Revenue$15.0M-9.5%

Operating income-$100.5M+16.8%

Net income-$96.2M+15.8%

EPS (diluted)-$0.81+26.4%

Cash & equivalents$134.7M+6.2%

Total debt$80.5M-32.5%

Total equity$620.9M-20.4%

Total assets$758.8M-23.1%

Operating cash flow-$117.3M+21.2%

CapEx$79.0K-89.3%

Free cash flow-$117.4M+21.5%

Market cap$2.17B+106%

Operating margin-636.6%-202pp

Net margin-597%-194pp

FCF margin-550.2%-140pp

Return on equity-56.3%-1.5pp

Debt / equity0.1×0.0×

Current ratio6.1×+1.2×

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnInvestments.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Intellia Therapeutics's gain (loss) on investments?: Intellia Therapeutics (NTLA) reported gain (loss) on investments of -$904K in Q1 2026.
How has Intellia Therapeutics's gain (loss) on investments changed year-over-year?: Intellia Therapeutics's gain (loss) on investments increased by 57.5% year-over-year, from -$2.13M to -$904K.